Alerta

CLOSED LOOP CONTROL OF PHYSIOLOGICAL GLUCOSE

Resumen de: EP4671882A2

The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.

ANTI-PLASMA KALLIKREIN ANTIBODY FORMULATIONS

Resumen de: WO2025264901A1

Disclosed herein are formulations of antibodies directed against plasma kallikrein, e.g., anti-plasma kallikrein antibodies. The formulations include, for example, amino acids, sugars, and surfactants. The disclosed formulations are useful for administration to subjects to treat plasma kallikrein associated disorders such as hereditary angioedema (HAE).

COMPUTER IMPLEMENTED METHOD FOR DETECTING AN OPERATION STATUS OF AN ANALYTE SENSOR FOR CONTINUOUS ANALYTE MONITORING, COMPUTER SYSTEM, COMPUTER PROGRAM PRODUCT, AND CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: WO2025261683A1

The present disclosure refers to a computer implemented method for detecting an operation status of an analyte sensor (10) for continuous monitoring an analyte, comprising: receiving continuous monitoring data for an analyte detected by an analyte sensor (10); detecting a loss of sensitivity for the analyte sensor (10), comprising determining a sensitivity indicator indicative of a sensor sensitivity of the analyte sensor (10) from the continuous monitoring data, providing a critical measure for the sensitivity indicator, and determining the loss of sensitivity for the analyte sensor (10), if the sensitivity indicator matches the critical measure for the sensitivity indicator; and detecting a defect status for the analyte sensor (10), comprising receiving an impedance value indicative of an impedance measured for the analyte sensor (10), providing a critical measure for the impedance of the analyte sensor (10), and determining the defect status for the analyte sensor (10), if the impedance value matches the critical measure for the impedance of the analyte sensor (10). A failure of the analyte sensor (10) is detected if for the analyte sensor (10) at least one of the loss of sensitivity and the defect status is determined, and, in response to detecting the failure of the analyte sensor (10), at least one of providing failure data indicative of the failure of the analyte sensor (10) and deactivating the analyte sensor (10) is conducted. Further, a computer system, a computer p

DYNAMIC MEASUREMENT OF CONSTITUENT CONCENTRATION IN AQUEOUS SOLUTIONS

Resumen de: US2025387548A1

Constituents of a liquid, such as blood, may exhibit optical signatures that allow for real-time, dynamic concentration detection. For example, concentrations of substances in aqueous solutions, including calcium, potassium, sodium, bicarbonate, chloride, magnesium, phosphate, lactate, acetate, glucose, creatinine, urea, and/or hydrogen peroxide, may be monitored during dialysis or other treatments. This is achieved by measuring real-time changes in light intensity at wavelengths corresponding to the constituents' optical signatures. Concentration may be determined using a predetermined relationship between light intensity and concentration at isolated wavelengths. Real-time monitoring enables timely treatment adjustments, improving patient outcomes.

TUBE CONNECTOR FOR AN INFUSION SET

Resumen de: US2025387561A1

The present disclosure relates to a tube connector (402) for an infusion set, for example for delivering insulin from an insulin pump. The tube connector includes a connector body (404) adapted for connection with a tube (406). The tube connector also includes opposing first and second latch arms (412, 414) resiliently joined to the connector body at flexing points (420, 422). The tube connector also includes a first lever (424) attached to the first latch arm and a second lever (426) attached to the second latch arm. The first and second levers extend alongside the first and second latch arms, respectively, such that pressing the first and second levers towards each other deflects the first and second latch arms relative to the body portion about the flexing points.

An Extended Duration Infusion System

Resumen de: US2025387564A1

An extended duration infusion set/system suitable for transcutaneous delivery of a treatment fluid to a subject is described. The infusion set reduces and delays fibrotic capsule formation on and around an infusion cannula, and increases the effective lifetime of an infusion set significantly. The infusion set comprises a deflectable therapy reservoir to “actively” diffuse insulin and negate the effects of the foreign body response (FBR).

DISPLAY FOR PUMP

Resumen de: US2025391384A1

An apparatus comprising a pump configured to deliver insulin, a processor, and a user interface including a color display. Color on the display can be used to bring a user's attention to a change in status of the device or a detected change in status of the patent.

PREVENTING YELLOWING AND FLUORESCENCE IN EPOXIDE DIAMINE NETWORKS

Resumen de: US2025387054A1

An encasement material that resists degradation, including yellowing. The encasement material may be used, for example, in an apparatus including a housing, circuitry at least partially within the housing, that is implanted into an animal (e.g. a human) to continuously monitor the concentrations of specific analytes, such as glucose. The encasement material allows for the efficient transmission of excitation and emission light to and from an analyte indicator in the device. The encasement material includes additives that resist and inhibit degradation of the encasement material thereby improving the longevity and life of the device. Also, methods for forming the encasement material and incorporating the encasement material within an apparatus.

NEEDLE RETRACTION ASSEMBLY FOR A DEVICE FOR DELIVERING INSULIN

Resumen de: WO2024173658A2

An infusion system comprising: a device configured to deliver medication to a user through an infusion catheter, wherein the device includes a housing configured to receive the infusion catheter and to maintain the infusion catheter in the user after insertion; and a detachable activation mechanism for deploying the device for delivering medication to the user, wherein the detachable activation mechanism comprises a trigger and a retraction mechanism that includes an introducer needle for introducing the infusion catheter into the user, wherein the detachable activation mechanism is configured to releasably connect to the housing, wherein the detachable activation mechanism is configured to insert the infusion catheter into the user, automatically release the detachable activation mechanism from the housing responsive to activation of the trigger and automatically retract the introducer needle into the needle retraction assembly to shield the needle upon the automatic release of the detachable activation mechanism.

MANUAL INSULIN PUMP CONFIGURATION

Resumen de: WO2025259242A1

The invention relates to a manually controlled manual insulin pump configuration suitable for use by diabetic individuals who have to inject with an insulin pen before each meal or high blood sugar correction dose.

OPTICAL SHORT-WAVE INFRARED SENSOR FOR BIOMEDICAL APPLICATIONS

Resumen de: WO2025258837A1

The present invention relates to an optical sensor and a wearable device comprising the same for non-invasively determining a concentration of blood components, for example, blood glucose and glycated hemoglobin levels. The optical sensor comprises an emitter configured to emit short-wave infrared (SWIR) radiation, an insulator with a channel transparent to the SWIR radiation, the emitter being disposed on top of the insulator and configured to emit the radiation into a biological tissue through the transparent channel, an optical concentrator made from a material with a refractive index of 1.7 or more, and a photodetector disposed in an upper part of the optical concentrator. The invention provides the possibility of non-invasive, instant or continuously monitoring of blood glucose and glycated hemoglobin levels. 2 indep. claims and 13 dep. claims, 15 figs., 2 tables.

METHOD OF DISPLAYING COMMUNICATION STATUS IN GLUCOSE MONITORING SYSTEM

Resumen de: US2025380912A1

One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off.

METHOD OF PROVIDING NOTIFICATION OF SIGNAL LOSS IN GLUCOSE MONITORING SYSTEM

Resumen de: AU2025201860A1

One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user. One embodiment may provide a method of providing a notification of signal loss in a glucose monitoring system, the method including, when a communication failure occurs between a terminal and a sensor transmitter, delaying a signal loss notification for a first period of time by the terminal, when the communication failure persists for the first period of time, further determining whether signal loss persists for a second period of time by the terminal, when the signal loss persists for the second period of time, generating the signal loss notification by the terminal, and outputting, by the terminal, the signal loss notification to a user.20 ar a r t o a u s e r Sensor module Sensor communicator Sensor controller Sensor storage 120 130 140 Outputter Communicator Controller Storage 220 230 240 ar a r

METHOD OF OUTPUTTNG BLOOD GLUCOSE DATA

Resumen de: AU2025202475A1

One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved. One embodiment may provide a method of outputting blood glucose data including obtaining biometric information in response to an advertisement transmitted by a sensor transmitter, generating the biometric information as output, in the case that a communication failure occurs, indicating a data gap during a period of the communication failure, and if the communication failure is resolved, filling the data gap during a period from a time point when the communication failure is resolved to one advertisement which arrives after the communication failure is resolved. pr p r c o m m u n i c a t i o n f a i l u r e i s r e s o l v e d @ pr p r

INTRAVASCULAR ARTIFICIAL PANCREAS

Resumen de: CN120787146A

Intravascular artificial pancreatic devices and methods of making the same are disclosed herein.

METHOD FOR TRANSMITTING/RECEIVING BIOMETRIC INFORMATION WITHOUT LOSS IN CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: EP4664482A2

The present disclosure relates to a method for transmitting or receiving biometric information in a continuous glucose monitoring system and, more specifically, to a method for transmitting or receiving biometric information, in which: when a sensor transmitter generates a transmission packet, the transmission packet is generated to include a generation identifier for identifying the transmission packet or biometric information according to a generation order of the transmission packet or the biometric information, and therefore the biometric information may be transmitted or received without a loss thereof via the generation identifier; and a transmission packet or biometric information, which a communication terminal has failed to receive, is correctly determined on the basis of a packet generation identifier or a total number of transmission packets, so that only biometric information or a transmission packet, which has failed to be received between the sensor transmitter and the communication terminal, may be transmitted or received in a distinguished manner.

METHOD OF DISPLAYING COMMUNICATION STATUS IN GLUCOSE MONITORING SYSTEM

Resumen de: EP4663120A1

One embodiment may provide a method of displaying a communication status in a glucose monitoring system, the method including displaying a communication status of a communication module in a terminal configured to transmit and receive data with a sensor transmitter, when the communication module is turned off, delaying a display of a communication module turn-off for one period of time by the terminal, and if the turn-off of the communication module persists for the one period of time, displaying the communication module turn-off.

MEMS PLATFORM TO CREATE FLUID SEAL AND PATH BETWEEN RESERVOIR AND CANNULA OF A DEVICE FOR DELIVERING INSULIN

Resumen de: WO2025255026A1

A device for delivering medication to a user, the device configured to be mounted to the user, the device comprising: (a) a baseplate and a housing configured to engage the baseplate to form an interior therein; (b) a platform mounted to the baseplate within the interior, the platform configured to support a micropump having an inlet port for communicating with a reservoir and an outlet port for communicating with a cannula for delivering the medication to the use.

GLUCOSE SENSOR USING A COMPACT AND COST-EFFECTIVE PHOSPHORESCENCE IMAGER AND MACHINE LEARNING

Resumen de: WO2025254973A1

A computational continuous glucose monitoring system is disclosed which integrates a biocompatible phosphorescence-based insertable sensor and a custom-designed phosphorescence imager (PI). This PI captures phosphorescence lifetime images of an insertable sensor through the skin where the lifetime of the emitted phosphorescence signal is modulated by the local concentration of glucose. The lifetime images acquired through the skin are processed by neural network-based models for misalignment-tolerant inference of glucose levels, accurately revealing normal, low (hypoglycemia) and high (hyperglycemia) concentration ranges. Using a 1-mm thick skin phantom mimicking the optical properties of human skin, in vitro testing of the PI using glucose-spiked samples yielded 88.8% inference accuracy, also showing resilience to random and unknown misalignments within a lateral distance of ~4.7 mm. Lateral misalignments beyond 5 mm prompted user intervention for re-alignment.

SIMPLIFIED INSULIN DELIVERY FOR DIABETICS

Resumen de: US2025375573A1

A simplified insulin pump allows diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.

NON-INVASIVE BLOOD GLUCOSE MONITORING DEVICE AND SYSTEM

Resumen de: WO2025253234A1

A system and method for non-invasive blood glucose level determination and proactive management are disclosed. A sensing device comprises a capacitance-to-digital converter (CDC) sensor, featuring an active shield electrode and single-ended mode operation, to measure capacitance variations indicative of net body charge modulation by systemic physiological activity correlated with blood glucose. The device also includes at least one skin conductance sensor. A processor determines blood glucose levels from combined CDC and skin conductance data, optionally using machine learning. Further, a proactive artificial intelligence (AI) system, employing supervised and reinforcement learning models, analyzes real-time and historical data to predict blood glucose trajectories and the likelihood of future dysregulation. Crucially, the AI dynamically generates a personalized schedule of recommended actions (e.g., relating to diet, exercise, or medication timing) for managing the subject's blood glucose, providing alerts and the action plan to enhance diabetes self-management.

METHOD FOR IMPROVING BLOOD GLUCOSE CONTROL OF A HYBRID CONTROLLER

Resumen de: US2025375574A1

A method for improving blood glucose control of a hybrid controller meal and exercise announcement by substituting patient-initiated meal boluses of said hybrid controller by an automatic insulin correction signal without retuning of said hybrid controller, and by incorporating rescue carbohydrates suggestion for hypoglycemia mitigation, comprising the steps of measuring a plasma glucose (G(t)) signal by means of a continuous glucose monitor (CGM), calculating a glucose level (Ĝ(t)) by using a glucose-insulin model; computing a disturbance term d(t), generating a virtual signal uIMC(t), for mitigating the effect of d(t) on the output, by means of an IMC filter Q(s) and converting the virtual signal uIMC(t) into three feed forward actions: insulin infusion, rescue carbohydrate suggestion, and insulin-on-board reduction.

Minimization of Noise in Optical Dat Capture for Liquids By Light Modulation Means

Resumen de: US2025377296A1

A process and sensor system with particular control of polarization of the interrogating light beams useful for determining a concentration of a targeted molecule M (such as glucose) within a given time period in a liquid sampling matrix through use of a Direct Infrared Laser Absorption Spectroscopy Technique.

HIGHLY INTEGRATED GLUCOSE SENSOR DEVICE

Resumen de: WO2024160808A1

The present disclosure relates to highly integrated sensor devices such as implantable devices, continuous monitoring devices and portable smart devices for determining a physiological parameter in a bodily fluid and/or tissue of a subject. Further, the present disclosure relates to methods for determining a physiological parameter in a bodily fluid and/or tissue of a subject.

PERSONALIZED CLOSED-LOOP INFUSION SYSTEM AND METHOD

Nº publicación: WO2025245938A1 04/12/2025

Solicitante:

MEDTRUM TECH INC [CN]
\u4E0A\u6D77\u79FB\u5B87\u79D1\u6280\u6709\u9650\u516C\u53F8

Resumen de: WO2025245938A1

A personalized closed-loop infusion system and method. Relevant information of patients is uploaded to a cloud server (104), and is grouped on the basis of identifiable features of the patients; the relevant information of different patients, such as blood glucose data records and insulin infusion data records, is compared in a same group; and when the relevant information of the patients is the same or similar, insulin algorithm parameters of patients with well-controlled blood glucose can be used for modifying an insulin algorithm of patients with poorly-controlled blood glucose, and a closed-loop artificial pancreas system can quickly obtain personalized insulin algorithms suitable for the patients without the need of long-period learning of physiological characteristics and lifestyle habits of the patients, thereby benefiting diabetes treatment of the patients.